Biotech Lab 4.0
Vaccine development by design
A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.
AchilleS Vaccines Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.
Our Technology
AchilleS Vaccines exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.
Next Generation Reverse Vaccinology (NGRV)
NGRV is an evolution of the classic Reverse Vaccinology method. NGRV exploits advanced laboratory and digital technologies for precise and rapid identification of more effective vaccine targets.
Homologous and heterologous antigen expression in bacterial vaccine platforms, high-throughput immunology, single cell and omics capabilities, analytic vaccinology and immortalized memory B-cells are among the tools and technologies which enable AchilleS Vaccines to perform Next Generation Reverse Vaccinology.
modified Outer Membrane Vesicles (mOMV)
A versatile technology platform that exploits bacteria for the production of self adjuvanting vesicles able to deliver antigenic molecules.
This technology has great advantages for product development, including large-scale, cost-effective production. mOMV have demonstrated good tolerability and high immunogenicity in humans.
MAbCo19
Covid-19 is a respiratory Coronavirus that has recently escalated worldwide to pandemic levels, becoming a Public Health Emergency of International Concern.
No licensed vaccines, immune therapeutics or effective drugs are currently available. The MAbCo19 project aims to rapidly deliver a human neutralizing monoclonal antibody as a prophylactic and therapeutic tool against Covid-19.
MalOMVax
Malaria still remains a grave infectious disease that impacts on the life and prosperity of the world population.
In recent times there have been over 200 million annual cases of malaria worldwide, leading to over 400.000 deaths. Children aged under 5 years are the most vulnerable group. Malaria can also be a predisposing co-morbidity for a number of other infections including fatal bacterial septicamias.
AchilleS Vaccines aims to move away from traditional approaches and use multidisciplinary, combinatorial, innovative science towards the development of a new malaria vaccine.
Solutions to fight AMR pathogens
Bacterial infections remain a serious threat for humanity. The increasing impact of antimicrobial resistance could create a global crisis with 10 million death per year in 2050.
We will use our R&D platforms to develop vaccines and immuno-therapeutics against Gram-negative bacteria that have a high level of antimicrobial resistance worldwide.
They Talk About Us
Latest News
-
Diesse and AchilleS Vaccines working together for new monoclonal antibody based therapies
Siena, 19 February 2021 – Diesse Diagnostica Senese and AchilleS Vaccines today announced the signing of a strategic agreement under which Diesse develops diagnostics tests
-
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2
Innovative monoclonal antibody developed by AchilleS can be administered intramuscularly, broadening access to COVID-19 treatment; Industrial development of Monoclonal antibody completed today and will
-
Momentum for monoclonal antibodies in the fight against Covid-19
In Europe, the fight against the Covid-19 pandemic was mainly focused on developing a vast number of vaccines through the use of different technologies. But
Scientific Collaborations
